Weaver Consulting Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Weaver Consulting Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$216K	Hold	1,373	–	–	0.04%	286
2026 Q2	$217K	Buy	+1,373	New	+$186K	0.04%	276
2020 Q4	–	Sell	-166	Closed	-$19K	–	916
2020 Q3	$19K	Hold	166	–	–	0.01%	417
2020 Q2	$19K	Buy	166 +42	+34%	+$4.14K	0.01%	397
2020 Q1	$10K	Hold	124	–	–	0.01%	454
2019 Q4	$10K	Hold	124	–	–	0.01%	501
2019 Q3	$11K	Hold	124	–	–	0.01%	468
2019 Q2	$11K	Hold	124	–	–	0.01%	448
2019 Q1	$10K	Buy	+124	New	+$10.5K	﹤0.01%	952

Other funds holding XBI

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.91% 1-Year Est. Return

Williams Jones Wealth Management New York $8.94B AUM 17.99% 1-Year Est. Return

Annex Advisory Services Brookfield, Wisconsin $6.11B AUM 13.75% 1-Year Est. Return

Weaver Consulting Group's XBI Position: Q3 2026 in Review

Weaver Consulting Group held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q3 2026 at 1,373 shares worth $216K. The position accounts for 0.04% of the portfolio, ranked #286.

Weaver Consulting Group first reported a position in XBI in Q1 2019 and has held it in 9 quarters since. The position peaked at $217K in Q2 2026. 521 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

Weaver Consulting Group held 1,373 shares of State Street SPDR S&P Biotech ETF worth $216K as of Q3 2026.
Weaver Consulting Group left its State Street SPDR S&P Biotech ETF share count unchanged in Q3 2026.
State Street SPDR S&P Biotech ETF made up 0.04% of Weaver Consulting Group's portfolio in Q3 2026, its #286 holding.
Weaver Consulting Group first reported a position in State Street SPDR S&P Biotech ETF in Q1 2019 and has held it in 9 quarters since.
Weaver Consulting Group's State Street SPDR S&P Biotech ETF position peaked at $217K in Q2 2026.
521 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Weaver Consulting Group's 13F filing for Q3 2026, filed 7 Oct 2026.